Frank A. Post

Frank A. Post

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 224 publications

Characteristics, impact and management of chronic pain in black women with HIV.

Characteristics, impact and management of chronic pain in black women with HIV.

Journal: International journal of STD & AIDS

Published: August 18, 2026

Associations between pain, mobility, quality of life and mental health in people of Black ethnicities with HIV in London.

Associations between pain, mobility, quality of life and mental health in people of Black ethnicities with HIV in London.

Journal: Journal of acquired immune deficiency syndromes (1999)

Published: July 24, 2026

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

Journal: Lancet (London, England)

Published: July 07, 2026

Protective Effect of the APOL1 p.N264K Variant Against CKD among People with HIV Carrying APOL1 High-Risk Genotypes.

Protective Effect of the APOL1 p.N264K Variant Against CKD among People with HIV Carrying APOL1 High-Risk Genotypes.

Journal: Journal of the American Society of Nephrology : JASN

Published: March 13, 2026

APOL1 Variants, AKI, and Progression to Kidney Failure in People of African Ancestry Living with HIV.

APOL1 Variants, AKI, and Progression to Kidney Failure in People of African Ancestry Living with HIV.

Journal: Kidney international reports

Published: March 05, 2026

Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial.

Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: March 03, 2026

The Impact of Recipient HIV Status on Kidney Transplant Outcomes in the United Kingdom: Have Previous Studies Overestimated Risk?

The Impact of Recipient HIV Status on Kidney Transplant Outcomes in the United Kingdom: Have Previous Studies Overestimated Risk?

Journal: Transplantation

Published: December 03, 2025

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir-based antiretroviral therapy.

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir-based antiretroviral therapy.

Journal: HIV medicine

Published: November 28, 2025

Renal Outcomes in People With HIV-1 and Renal Impairment Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide: Integrated Analysis From 9 Phase 3/3b Clinical Trials.

Renal Outcomes in People With HIV-1 and Renal Impairment Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide: Integrated Analysis From 9 Phase 3/3b Clinical Trials.

Journal: Open forum infectious diseases

Published: November 17, 2025

Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial.

Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial.

Journal: The Lancet. Infectious diseases

Published: September 02, 2025

Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial.

Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial.

Journal: The Lancet. Infectious diseases

Published: September 02, 2025

Associations between plasma biomarkers and changes in cognitive function over two years in people with and without HIV.

Associations between plasma biomarkers and changes in cognitive function over two years in people with and without HIV.

Journal: AIDS (London, England)

Published: August 28, 2025

Showing 1-12 of 224

Last Updated: 09/26/2026